Clinical Trials Browser

Phase 2 × Leukemia, Myeloid, Acute × Dasatinib × Clear all

Leukemia, Myeloid, Acute

NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02113319 2014-04-14

DasaCBF

Phase 2 Completed

27 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

VEN-R DASA

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

DasaCBF